New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali

信号蛋白-丛蛋白信号介导的血栓形成和炎症的新途径

• 批准号: 7934002
• 负责人: Guy A. Zimmerman
• 金额: $ 49.83万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7934002
• 关键词: Acute Lung Injury; Address; Adherence; Age; Anticoagulants; Area; Aspirin; Binding; Biochemical; Biological; Biological Models; Blood Platelets; Blood Vessels; Cardiovascular system; Cell Adhesion Molecules; Cell Communication; Cell model; Cells; Characteristics; Clinical; Clinical Research; Coagulation Process; Communication; Communities; Complex; Cues; Cyclooxygenase Inhibitors; Cytoskeletal Modeling; Data; Diagnosis; Disease; Distal; Endothelium; Erythrocytes; Event; Experimental Models; Family; Family member; Future; Gene Expression; Goals; Grant; Health; Heart; Hematological Disease; Hemostatic Agents; Hemostatic function; Heparin; Human; In Vitro; Inflammation; Inflammatory; Inflammatory Response; Integrins; Intervention; Investigation; Knowledge; Lead; Leukocytes; Ligands; Link; Lung; Measures; Mediating; Mediator of activation protein; Messenger RNA; Mission; Molecular; Molecular Target; Mus; Myocardial Infarction; Nervous system structure; Neurons; Pathogenesis; Pathologic; Pathway interactions; Patients; Pattern; Pharmacologic Substance; Platelet Activation; Public Health; Recombinants; Research Personnel; Role; Sampling; Semaphorins; Sepsis; Septicemia; Severities; Signal Pathway; Signal Transduction; Signaling Molecule; Stroke; Syndrome; Technical Expertise; Testing; Therapeutic Agents; Thrombosis; Thrombus; Vascular Diseases; Warfarin; acute coronary syndrome; axon growth; base; clopidogrel; healthy volunteer; improved; in vivo; in vivo Model; meetings; neuronal guidance; novel; novel therapeutics; plexin; pre-clinical; preclinical study; protein expression; public health relevance; receptor; research study; response; septic; thienopyridine

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (04), Clinical Research, and specific Challenge Topic 04-HL-103: assess the role of leukocyte interaction with platelets, erythrocytes, and endothelium in the pathogenesis of heart, lung, and blood diseases. Our proposal explores a new paradigm in molecular signaling and cell-cell interactions that is broadly relevant to human thrombotic and inflammatory diseases, and has the potential to generate novel therapeutic strategies and agents in addition to providing new knowledge in the field. The project unites a team of established investigators that is uniquely well-suited to examine clinically-applicable and basic questions relevant to the pathobiology of hemostasis and inflammation, builds on new discoveries that we have recently made, and poses focused aims that can be addressed expeditiously with expertise and technical capabilities that are in place in our collaborative group. The project is thus poised for rapid translational investigation and, potentially, fast track application. These features make it ideal for the Challenge Grant initiative. Thrombosis and inflammation are intricately linked in the pathogenesis of acute coronary syndromes, stroke, sepsis, acute lung injury, and a variety of other devastating human disorders. While much is known, there remain major gaps in our knowledge regarding the molecular pathways and cellular events that integrate inflammatory and hemostatic signaling in health, and mediate dysregulated signaling in disease. We have discovered a previously-unrecognized pathway that has these critical characteristics. Semaphorin-plexin D1 signaling has recently-identified roles in cellular guidance in the nervous system, but was not known to influence platelet activation, platelet-leukocyte interactions, or hemostatic and inflammatory events in vivo. Our preliminary data yield strong evidence that the semaphorin-plexin D1 signaling axis directly influences each of these, and that it may therefore be a novel target for molecular intervention. Because our current evidence indicates that semaphorin-plexin D1 signaling alters prothrombotic responses of activated platelets by modifying intracellular checkpoints and cytoskeletal organization distal to receptor-mediated cellular activation, new therapeutic agents that target this pathway could potentially be used independently or in combination with other antithrombotic therapies including cyclooxygenase inhibitors (aspirin), thienopyridines (clopidogrel), and anticoagulants (heparin, warfarin). The inter-related specific aims that we propose employ in vitro studies in informative human cell models, in vivo models carefully chosen for preclinical relevance and correlation with the in vitro experiments, and analyses of patient samples, and will rapidly advance our basic, translational, and clinical understanding of semaphorin-plexin signaling in hemostasis, inflammation, and vascular disease. The project will also form the basis for future investigations in many other experimental models and a variety of human syndromes. Our studies will exploit scientific and clinical opportunities, have the potential for broad and major impact, and will influence paradigms in diverse scientific and translational communities. Our proposal is thus directly responsive to the Challenge Grant goals and missions. PUBLIC HEALTH RELEVANCE: The investigations outlined in this proposal will address cellular and biochemical mechanisms that contribute to thrombotic and inflammatory diseases, which are major public health problems. Unregulated thrombosis (clot formation, often occluding blood vessels) and inflammation contribute directly to heart attack, stroke, sepsis ("blood poisoning"), acute lung injury, and a host of other devastating human disorders. Many gaps in our understanding of these disease and disorders remain, limiting our ability to develop new and improved therapies and preventative measures. The molecular pathway that we have discovered and will examine in this proposal is a potential target for new and novel molecular therapies. Our studies will also provide invaluable new information on how clot formation and inflammation are controlled in health, and become uncontrolled and injurious in disease.

描述（由申请人提供）：本申请涉及广泛的挑战领域（04）、临床研究和特定的挑战主题04- hl -103：评估白细胞与血小板、红细胞和内皮细胞相互作用在心脏、肺和血液疾病发病机制中的作用。我们的提案探索了分子信号和细胞-细胞相互作用的新范式，这与人类血栓性和炎症性疾病广泛相关，并且除了提供该领域的新知识外，还具有产生新的治疗策略和药物的潜力。该项目联合了一组成熟的研究人员，他们非常适合研究与止血和炎症病理生物学相关的临床应用和基本问题，建立在我们最近取得的新发现的基础上，并提出了可以通过我们合作小组的专业知识和技术能力迅速解决的重点目标。因此，该项目为快速转化调查和潜在的快速应用做好了准备。这些特点使它成为挑战奖助金计划的理想选择。血栓和炎症在急性冠状动脉综合征、中风、败血症、急性肺损伤和各种其他破坏性人类疾病的发病机制中有着错综复杂的联系。虽然我们知道很多，但我们对健康中整合炎症和止血信号并介导疾病中失调信号的分子途径和细胞事件的了解仍然存在重大差距。我们发现了一种以前未被认识到的途径，它具有这些关键特征。信号素丛蛋白D1信号最近被发现在神经系统的细胞引导中起作用，但不知道在体内影响血小板活化、血小板-白细胞相互作用或止血和炎症事件。我们的初步数据提供了强有力的证据，表明信号素丛蛋白D1信号轴直接影响这些，因此它可能是分子干预的新靶点。因为我们目前的证据表明，信号素丛蛋白D1信号通过改变细胞内检查点和细胞骨架组织来改变活化血小板的血栓前反应，而受体介导的细胞激活远端，针对这一途径的新治疗剂可能单独使用或与其他抗血栓治疗药物联合使用，包括环氧化酶抑制剂（阿司匹林）、噻吩吡啶（氯吡格雷）和抗凝血剂（肝素）。华法令阻凝剂)。我们提出的相互关联的具体目标是在体外研究中提供信息的人类细胞模型，精心选择的临床前相关性和与体外实验的相关性的体内模型，以及患者样本的分析，并将迅速推进我们对止血，炎症和血管疾病中信号通路的基础，转化和临床理解。该项目还将为未来许多其他实验模型和各种人类综合症的研究奠定基础。我们的研究将利用科学和临床机会，具有广泛和重大影响的潜力，并将影响各种科学和转化社区的范式。因此，我们的提案直接回应挑战奖助金的目标与使命。